Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes

被引:85
|
作者
Sindelar, JL
Jofre-Bonet, M
French, MT
McLellan, AT
机构
[1] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, New Haven, CT 06520 USA
[3] Natl Bur Econ Res, Cambridge, MA 02138 USA
[4] London Sch Hyg & Trop Med, London WC2A 2AE, England
[5] Univ London London Sch Econ & Polit Sci, Dept Econ, London WC2A 2AE, England
[6] Univ Miami, Dept Sociol, Coral Gables, FL 33124 USA
[7] Univ Penn, Treatment Res Inst, Dept Psychiat, Philadelphia, PA 19106 USA
关键词
cost-effectiveness analysis; treatment; services; economics;
D O I
10.1016/j.drugalcdep.2003.09.002
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This paper identifies and illustrates the challenges of conducting cost-effectiveness analysis (CEA) of addiction treatments given the multiple important outcomes of substance abuse treatment (SAT). Potential problems arise because CEA is intended primarily for single outcome programs, yet addiction treatment results in a variety of outcomes such as reduced drug use and crime and increased employment. Methodological principles, empirical examples, and practical advice are offered on how to conduct an economic evaluation given multiple outcomes. An empirical example is provided to illustrate some of the conflicts in cost-effectiveness (CE) ratios that may arise across the range of outcomes. The data are from the Philadelphia Target Cities quasi-experimental field study of standard versus "enhanced" (e.g. case management and added social services) drug treatment. Outcomes are derived from of the Addiction Severity Index (ASI), while cost data were collected and analyzed using the Drug Abuse Treatment Cost Analysis Program (DATCAP). While the results are illustrative only, they indicate that cost-effectiveness ratios for each of several different outcomes can produce conflicting implications. These findings suggest that multiple outcomes should be considered in any economic analysis of addiction treatments because focusing on a single outcome may lead to inadequate and possibly incorrect policy inferences. However, incorporating multiple outcomes into a CEA of addiction treatment is difficult. Cost-benefit analysis (CBA) may be a preferable and more appropriate approach in some cases. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan
    Machida, Hiroko
    Matsuo, Koji
    Higashi, Takahiro
    Aoki, Daisuke
    Enomoto, Takayuki
    Okamoto, Aikou
    Katabuchi, Hidetaka
    Nagase, Satoru
    Mandai, Masaki
    Yaegashi, Nobuo
    Yamagami, Wataru
    Mikami, Mikio
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [22] Operative Treatment of Primary Hyperparathyroidism Balancing Cost-effectiveness Outcomes
    Elaraj, Dina
    Sturgeon, Cord
    SURGICAL CLINICS OF NORTH AMERICA, 2014, 94 (03) : 607 - +
  • [23] Cost-effectiveness analysis
    Stein, Sherman C.
    Malhotra, Neil R.
    Burnett, Mark G.
    JOURNAL OF NEUROSURGERY-SPINE, 2014, 20 (04) : 474 - 474
  • [24] COST-EFFECTIVENESS ANALYSIS
    GANIATS, TG
    PRIMARY CARE, 1995, 22 (02): : 307 - 318
  • [25] Cost-effectiveness analysis
    Yates, BT
    EVALUATION AND PROGRAM PLANNING, 2002, 25 (02) : 201 - 202
  • [26] COST-EFFECTIVENESS ANALYSIS
    BALAKRISHNA, S
    JOURNAL OF RURAL DEVELOPMENT, 1992, 11 (05) : 701 - 703
  • [27] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Moogeh Baharnoori
    Virender Bhan
    Fraser Clift
    Kimberly Thomas
    Soukaïna Mouallif
    Nicholas Adlard
    Philip Cooney
    François Blanchette
    Barkha P. Patel
    Daniel Grima
    PharmacoEconomics - Open, 2022, 6 : 859 - 870
  • [28] Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis
    Gong, Cynthia L.
    Studdert, Ann L.
    Liedtke, Michaela
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) : E68 - E70
  • [29] TREATMENT IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS IN MACEDONIA: DEVELOPMENT OF COST-EFFECTIVENESS ANALYSIS
    Qerimi, V
    Kapedanovska-Nestorovska, A.
    Sterjev, Z.
    Genadieva-Stavric, S.
    Suturkova, L.
    VALUE IN HEALTH, 2017, 20 (09) : A435 - A435
  • [30] COST-EFFECTIVENESS ANALYSIS OF DACLIZUMAB BETA IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN ITALY
    Demma, R.
    Casamassima, G.
    Cocco, E.
    Di Turi, R.
    Paolicelli, D.
    Fantaccini, S.
    Santoni, L.
    Fumeri, G.
    VALUE IN HEALTH, 2017, 20 (09) : A723 - A723